A 4-Week, Randomised, Double-Blind, Multicentre, Dose-Finding Phase IIb Study With AZD0865 25, 50, 75 Mg and Esomeprazole 20 Mg, Given Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis According to the LA Classification in Adult Subjects.

Trial Profile

A 4-Week, Randomised, Double-Blind, Multicentre, Dose-Finding Phase IIb Study With AZD0865 25, 50, 75 Mg and Esomeprazole 20 Mg, Given Orally Once Daily for the Treatment of GERD Without Erosive Esophagitis According to the LA Classification in Adult Subjects.

Completed
Phase of Trial: Phase II

Latest Information Update: 25 Aug 2009

At a glance

  • Drugs AZD 0865; Esomeprazole
  • Indications Gastro-oesophageal reflux; Heartburn
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 25 Aug 2009 Actual end date (Apr 2005) added as reported by ClinicalTrials.gov.
    • 09 Sep 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top